Advisor Group Holdings, Inc. Rapt Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.89 - $9.38 $260 - $844	90 New	90 $0
Q4 2023 Feb 12, 2024	BUY	$11.28 - $25.46 $6,598 - $14,894	585 Added 283.98%	791 $19,000
Q3 2023 Nov 13, 2023	SELL	$16.34 - $24.66 $1,944 - $2,934	-119 Reduced 36.62%	206 $3,000
Q1 2023 May 12, 2023	BUY	$17.19 - $30.8 $2,148 - $3,850	125 Added 62.5%	325 $5,000
Q3 2021 Nov 05, 2021	BUY	$29.86 - $39.47 $5,972 - $7,894	200 New	200 $6,000
Q2 2021 Aug 02, 2021	SELL	$17.99 - $40.02 $17,990 - $40,020	-1,000 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$15.89 - $40.87 $13,506 - $34,739	850 Added 566.67%	1,000 $20,000
Q1 2020 May 18, 2020	BUY	$11.86 - $48.86 $1,779 - $7,329	150 New	150 $3,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $36.5M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.